The global Raman analyzers market was valued at US$ 585.5 Mn in 2021. Sales of Raman analyzers are set to exhibit 4.8% CAGR and reach US$ 970.8 Mn by 2032.
Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/22897
Endoscopic submucosal dissection (ESD) has been the most significant advancement in therapeutic endoscopy in recent years for the management of early gastric cancer. Because there are few cases with relevant indicators, ESD is not well-known in the West. This is due to lower rates of the disease than in Japan, as well as a lack of adequate screening systems. As a result, early detection of stomach cancer is extremely rare. Furthermore, histopathologic criteria for early mucosal intestine cancer differ between Japanese and Western pathologists. As a result, bulk of early cancer diagnoses made by Japanese pathologists would go unnoticed in the West. Nonetheless, ESD is a method that is still being refined, and its acceptability and use are increasing.
With expanded experience and new developments in endoscopic procedures, ESD has grown in popularity in the United States over the last decade. With additional research evaluating the safety of colorectal ESD and improvements in endoscopists’ expertise, the treatment has grown in popularity in recent years.
Company Profiles:
- FUJIFILM Holdings Corp
- Olympus Corporation
- Heritage Electromedicine GmbH
- Sumitomo Bakelite Co., Ltd.
- Ovesco Endoscopy AG
- Boston Scientific Corporation
- Zeon Corporation
- Cook Group
- CONMED Corporation
- STERIS
Key Takeaways from Market Study
- Knives, under the product category for endoscopic submucosal dissection, held a market share of 34.3% in 2021.
- Stomach cancer indication accounted for the highest market share of 81% by value in 2021.
- Hospitals accounted for a market share of around 44.8% in 2021 and the segment is set to advance at a CAGR value of 6.6% through 2032.
- The East Asian region accounted for 57% of the global market share in 2021.